Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.

With regards to HR status, among the HR-population in the Study 301, although the OS and PFS of the Eribulin group were longer than those of the capecitabine group, the difference did not reach statistical significance (p = 0.05 and 0.82, respectively) [ 25 ].

also in 111,027 other papers